| Item Type | Name |
|
Concept
|
Anticoagulants
|
|
Academic Article
|
The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results.
|
|
Academic Article
|
Aspirin dose and six-month outcome after an acute coronary syndrome.
|
|
Academic Article
|
Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy.
|
|
Academic Article
|
Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease.
|
|
Academic Article
|
Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - a direct and selective antagonist.
|
|
Academic Article
|
The potential of aptamers as anticoagulants.
|
|
Academic Article
|
Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease.
|
|
Academic Article
|
Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes.
|
|
Academic Article
|
Platelet inhibitor therapy for patients with cardiovascular disease: looking toward the future.
|
|
Academic Article
|
Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative.
|
|
Academic Article
|
Advances in antithrombotic therapy in acute myocardial infarction: the ExTRACT-TIMI 25 and OASIS-6 Trials.
|
|
Academic Article
|
Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative.
|
|
Academic Article
|
First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.
|
|
Academic Article
|
Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials.
|
|
Academic Article
|
Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes.
|
|
Academic Article
|
Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice.
|
|
Academic Article
|
Patterns of management of atrial fibrillation complicating coronary artery bypass grafting: Results from the PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT-IV) Trial.
|
|
Academic Article
|
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial.
|
|
Academic Article
|
Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes.
|
|
Academic Article
|
First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention.
|
|
Academic Article
|
Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, S?o Paulo, Brazil.
|
|
Academic Article
|
Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20-21, 2011, Salvador, Bahia, Brazil.
|
|
Academic Article
|
Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy.
|
|
Academic Article
|
Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
|
|
Academic Article
|
Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trial.
|
|
Academic Article
|
Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients: An Unmet Need.
|
|
Academic Article
|
Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).
|
|
Academic Article
|
The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.
|
|
Academic Article
|
Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy.
|
|
Academic Article
|
Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX).
|
|
Academic Article
|
Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy.
|
|
Academic Article
|
Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial.
|
|
Academic Article
|
Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial).
|
|
Academic Article
|
Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients.
|
|
Academic Article
|
Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial.
|
|
Academic Article
|
Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial.
|
|
Academic Article
|
Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy.
|
|
Academic Article
|
Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention.
|
|
Academic Article
|
First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation.
|
|
Academic Article
|
Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
|
|
Academic Article
|
Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
|
|
Academic Article
|
Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial.
|
|
Academic Article
|
Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
|
|
Academic Article
|
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
|
|
Academic Article
|
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
|
|
Academic Article
|
Management of Antithrombotic Therapy after Acute Coronary Syndromes.
|
|
Academic Article
|
Antithrombotic Therapy after Acute Coronary Syndromes. Reply.
|
|
Academic Article
|
Antithrombotics in acute coronary syndromes.
|
|
Academic Article
|
Inverse relationship between body mass index and risk of venous thromboembolism among medically ill hospitalized patients: Observations from the APEX trial.
|
|
Academic Article
|
External validation of the ADA score for predicting thrombosis among acutely ill hospitalized medical patients from the APEX Trial.
|